Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

[N-((2S,3R,3aS,3R,4aR,6S,6aR,6bS,7aR,12aS,12bS,Z)-3,6,11,12b-tetramethyl-2,3a,3,4,4,4a,5,5,6,6,6a,6b,7,7a,7,8,10,12,12a,12b-icosahydro-1H,3H-spiro[furo[3,2-b]pyridine-2,9-naphtho[2,1-a]azulene]-3-yl)methanesulfonamide hydrochloride]

EU orphan designation number: EU/3/11/859
Active ingredient: [N-((2S,3R,3aS,3´R,4a´R,6S,6a´R,6b´S,7aR,12a´S,12b´S,Z)-3,6,11´,12b´-tetramethyl-2´,3a,3´,4,4´,4a´,5,5´,6,6´,6a´,6b´,7,7a,7´,8´,10´,12´,12a´,12b´-icosahydro-1´H,3H-spiro[furo[3,2-b]pyridine-2,9´-naphtho[2,1-a]azulene]-3´-yl)methanesulfonamide hydrochloride]
Indication: Treatment of chondrosarcoma
Sponsor: Voisin Consulting S.A.R.L.
3 rue des Longs Prés, F-92100 Boulogne-Billancourt, France

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/05/2011 Centralised Orphan - Designation EMA/OD/143/10 (2011)3485 of 13/05/2011
18/07/2013 Centralised Orphan - Removal of orphan designation from Community Register